Dialysis patients may soon say goodbye to strict low-potassium diets

NCT ID NCT06858280

Recruiting now Disease control Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether the drug patiromer can safely allow people on chronic dialysis to relax their strict low-potassium diet. About 40 participants will receive either patiromer or a placebo daily. The goal is to see if patiromer keeps potassium levels stable while patients eat more potassium-rich foods, potentially improving their nutrition and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: patiromer (Veltassa)
What this could lead to: If it works, this could allow dialysis patients to eat a more varied diet without risking dangerous potassium spikes, improving their quality of life.
What could go wrong: This is a small pilot trial with only 40 participants, so results may not apply to everyone. Patiromer can cause stomach upset or interact with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 AND 4 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure Hyperkalemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE STAGE 3 AND 4 DIETARY INTERVENTION HYPERKALAEMIA

Contacts and locations

Locations

Nephrology Unit, ASST Papa Giovanni XXIII
RECRUITING

Bergamo, BG, 24127, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.